From Berkshire Hathaway's - Business Wire
CONCORD, Calif.--(BUSINESS WIRE)-- Cerus Corporation (Nasdaq: CERS) today announced financial results for the fourth quarter and year ended December 31, 2017.
Recent developments and highlights include:
*Reported record fourth quarter product revenue of $16.2 million, an increase of 60% compared to the
same period in the year prior.
*Established 2018 annual product revenue guidance of $51 million to $53 million, which would
represent a
17% to 22% increase over 2017 reported product revenue.
*Successfully met primary safety and efficacy endpoints in SPARC, Cerus’ European Phase 3 clinical trial *evaluating INTERCEPT red cell transfusions in thalassemia patients.
*Completed an underwritten public offering of common stock raising gross proceeds of $57.5 million.
*Advanced release assay for commercial manufacturing of the S303 compound used in the INTERCEPT
red blood cell system to enable H2 2018 CE Mark submission.
IMO it is up from here and a buy at $5.
CONCORD, Calif.--(BUSINESS WIRE)-- Cerus Corporation (Nasdaq: CERS) today announced financial results for the fourth quarter and year ended December 31, 2017.
Recent developments and highlights include:
*Reported record fourth quarter product revenue of $16.2 million, an increase of 60% compared to the
same period in the year prior.
*Established 2018 annual product revenue guidance of $51 million to $53 million, which would
represent a
17% to 22% increase over 2017 reported product revenue.
*Successfully met primary safety and efficacy endpoints in SPARC, Cerus’ European Phase 3 clinical trial *evaluating INTERCEPT red cell transfusions in thalassemia patients.
*Completed an underwritten public offering of common stock raising gross proceeds of $57.5 million.
*Advanced release assay for commercial manufacturing of the S303 compound used in the INTERCEPT
red blood cell system to enable H2 2018 CE Mark submission.
IMO it is up from here and a buy at $5.